US FDA approves Shire's new paediatric ADHD drug
This article was originally published in Scrip
Executive Summary
The US FDA has approved Shire's once-daily Intuniv (guanfacine) extended release tablets for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged six to 17 years. Shire plans to start selling the product in the US, in four dosage strengths, in November.